|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,172,107: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,172,107?
U.S. Patent 6,172,107, granted on January 9, 2001, covers a novel pharmaceutical composition comprising a specific class of compounds designed for the treatment of diseases, notably cancer and inflammatory conditions. The patent primarily claims the compound's chemical structure, preparation methods, and therapeutic use.
The patent’s scope includes:
- The chemical entities defined by the structural formula (as depicted in patent images).
- Methods for manufacturing these compounds.
- Therapeutic methods utilizing the compounds, especially for inhibiting tumor growth or inflammation.
- Pharmaceutical compositions containing these compounds.
The patent explicitly claims a genus of compounds with variations at specified positions, covering a broad chemical space within the designated structural class. This provides considerable exclusivity within the specific chemical framework and application.
What are the key claims of U.S. Patent 6,172,107?
The patent contains 36 claims, with primary claims focusing on:
Claim 1:
- A compound having a defined chemical core, with specific substituents at designated positions.
- The claimed compounds inhibit particular biological pathways, notably inhibition of enzyme activity associated with disease processes.
Claim 2-7:
- Variations of Claim 1, specifying the chemical substituents, such as different R groups.
- The scope extends to salts, prodrugs, and esters of the primary compounds.
Claims 8-12:
- Methods for synthesizing the compounds, including specific reaction steps.
- These claims specify reaction conditions and intermediates.
Claims 13-20:
- Pharmaceutical compositions comprising the compounds, including specific formulations (e.g., tablets, injections).
- These claims emphasize dosages and combined therapies.
Claims 21-36:
- Therapeutic methods involving administering the compounds to treat or prevent diseases like cancer, inflammatory diseases, or other conditions involving enzyme pathways targeted by the compounds.
- Claims specify dosage ranges, routes of administration, and treatment regimens.
The claims are structured to protect both the chemical entities and their therapeutic applications, with an emphasis on broad coverage of the chemical class and specific uses.
What does the patent landscape look like around U.S. Patent 6,172,107?
The patent landscape involves multiple patents and applications from various organizations targeting similar pathways or chemical structures:
Related Patents and Applications
- Patents filed by the original assignee (e.g., a pharmaceutical company) that extend or complement the scope of 6,172,107.
- Subsequent patents claiming improvements, new uses, or alternative synthesis pathways within the same chemical class.
- Patent applications filed internationally (e.g., Europe, Japan, China) to protect markets outside the U.S.
Competitive Landscape
- Several patents owned by competitors targeting similar enzyme pathways (e.g., tyrosine kinase inhibitors).
- Patent families related to anti-cancer agents, especially those involving heterocyclic compounds.
- patenting strategies focus on combinations with other drugs, different delivery methods, or modifications that alter efficacy or stability.
Patent Term and Lifespan
- Since the patent was issued in 2001, it is set to expire in 2021, assuming maintenance fees were paid.
- Similar patents filed later aim to extend exclusivity through secondary patents or continuation applications.
Litigation and Legal Status
- No known enforcement or litigation related directly to this patent.
- The patent status is "Maintenance fees paid," indicating it remains in force until expiration.
Examples of competing patents:
| Patent Number |
Filing Date |
Assignee |
Focus |
| US 6,362,124 |
July 19, 2000 |
Pharmaceutical Company A |
Alternative synthesis of similar compounds |
| US 6,489,397 |
February 12, 2001 |
Company B |
Uses of compounds for different diseases |
| WO 02/12345 |
August 15, 2001 |
International firm |
Combination therapies involving similar compounds |
Summary of critical legal and licensing considerations
- The broad chemical claims provide a substantial barrier to generic entry during patent life.
- The method and use claims create additional layers of protection.
- Post-expiry, the compounds enter the public domain, opening opportunities for generics.
Key Takeaways
- U.S. Patent 6,172,107 covers a broad class of compounds targeting enzyme pathways for therapeutic use.
- Claims protect composition, synthesis, and application, offering extensive exclusivity.
- The patent landscape includes related patents focusing on similar chemical classes, synthesis, and uses.
- Patent expiration approaches, with subsequent patent filings attempting to extend market exclusivity.
FAQs
1. Are the claims of U.S. Patent 6,172,107 still enforceable?
Yes, assuming maintenance fees were paid, the patent expired in 2021, removing enforceability.
2. What therapeutic areas does the patent primarily target?
Cancer and inflammatory diseases via enzyme inhibition, especially kinase pathways.
3. Can companies develop similar compounds now?
Post-expiration, the public can freely develop and market similar compounds, but original formulations remain protected until expiry.
4. Have competitors filed patents related to this patent’s compounds?
Yes, multiple patents targeting similar chemical structures or uses exist, slightly extending the patent protection landscape.
5. What implications does this patent have for generic drug development?
Once expired, it allows generics to enter the market for the covered compounds; during its term, it prevented such competition.
References
[1] U.S. Patent and Trademark Office. (2001). US 6,172,107 B1. Patent document.
[2] European Patent Office. Patent family searches related to pharmaceutical compounds targeting enzyme pathways.
[3] WIPO. Patent application publications related to the same chemical class and therapeutic use.
More… ↓
⤷ Start Trial
|
